Gilead Sciences, Inc.

Kristyna M Elbel

Britton Kenneth Corkey

Rao V Kalla

Thao Perry

Samuel E Metobo

Evangelos Aktoudianakis

David Sperandio

Hai Yang

Mark J Bartlett

Jeff A Zablocki

Xiaofen Li

Jinfa Du

Tetsuya Kobayashi

Robert H Jiang

Michael R Mish

Julian Andrew Codelli

Ruben Martinez

Gregory F Chin

Jennifer Leigh Cosman

Sophie Shevick

Elfatih O Elzein

Scott A Mitchell

Dmitry Koltun

Rick Andrew Lee

Eric Q Parkhill

Jayaraman Chandrasekhar

Scott Preston Simonovich

John H Conway

Christopher Allen Ziebenhaus

Manuel Munoz

Suet Chung Yeung

Joshua J Van Veldhuizen

Jennifer Alissa Loyer-Drew

Eifatih Elzein

The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

Substituted eneoxindoles and uses thereof

Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed: 

Therapeutic heterocyclic compounds

Compounds having the following Formula (I), or a pharmaceutically acceptable salt or pharmaceutically acceptable tautomer thereof, and methods of their use and preparation are disclosed: 

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R, R, R, R, R, R, R, and Rare described herein.

Benzimidazole derivatives as bromodomain inhibitors

The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R, R, R, R, R, and Rare as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

Benzimidazole and imadazopyridine carboximidamide compounds

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R, R, R, R, R, and X are described herein.

Benzimidazolone derivatives as bromodomain inhibitors

Growing community of inventors

South San Francisco, CA, United States of America

Kristyna M Elbel